Overview

Aripiprazole Once-monthly in Patients With Schizophrenia

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
To obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed Study 14724A / NCT01795547.
Phase:
Phase 3
Details
Lead Sponsor:
H. Lundbeck A/S
Collaborator:
Otsuka Pharmaceutical Co., Ltd.
Treatments:
Aripiprazole